Registry study evaluates performance and clinical outcomes of the SAPIEN 3 Ultra RESILIA valve in patients undergoing aortic replacement, highlighting real-world device safety.
Data on the performance of the latest-generation SAPIEN 3 Ultra RESILIA (S3UR) valve in patients who undergo transcatheter aortic valve replacement (TAVR) are scarce.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: